A national portfolio of bone oncology trials-The Canadian experience in 2012

Journal of Bone Oncology

Volumn 1, Issue 3, 2012, Pages 95-100

  Kuchuk, I ^a   Simos, D ^a   Addison, C L ^b   Clemons, M ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Bisphosphonates; Bone; Bone metastasis; Bone treatment; Cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; DEXAMETHASONE; DOXYCYCLINE; FULVESTRANT; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; VANDETANIB; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BASIC RESEARCH; BONE CANCER; BONE MARROW BIOPSY; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; BREAST METASTASIS; CANADA; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); DRUG SAFETY; HUMAN; LOCAL THERAPY; MAXIMUM TOLERATED DOSE; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; OSTEOCLAST ACTIVITY; OSTEOSARCOMA; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOSURGERY; RETREATMENT; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SOLID TUMOR; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; ULTRASOUND SURGERY; UNSPECIFIED SIDE EFFECT;

EID: 84875621693     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.09.001     Document Type: Review

References (43)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews 2001;27:165-76.
2. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncology 2011;12:631-41.
3. Coleman RE, Marshall H, David Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine 2011;365:1396-405.
4. Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13: 734-42.
5. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. Lancet 2012;379(9810):39-46.
6. A phase III international randomized trial of single versus multiple fractions for re-irradiation of painful bone metastases, .
7. A phase III study of the effect of re-irradiation for bone pain on urinary markers of osteoclast activity, < http://www.canadiancancertrials.ca/ >.
8. A randomized phase iii double-blind study of dexamethasone versus placebo in the prophylaxis of radiation-induced pain flare following palliative radiotherapy for bone metastases, .
9. A prospective cohort study of the role of surgery and/or radiotherapy for bone metastases of the femur at high risk of pathological fracture, < http:// clinicaltrials.gov/ct2/show/NCT01428895 >.
10. Surgical versus nonoperative treatment of metastatic epidural spinal cord compression. Quality of life and cost-effectiveness outcomes, .
11. A pivotal study to evaluate the effectiveness and safety of ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) treatment of metastatic and multiple myeloma bone tumors for the palliation of pain in patients who are not candidates for radiation therapy, < http://clinicaltrials.gov/ct2/show/ NCT00656305>.
12. Phase II/III study of image-guided radiosurgery/SBRT for localized spine metastasis, < http://clinicaltrials.gov/ct2/show/NCT00922974> .
13. A randomized pilot study comparing the efficacy of 4-weekly versus 12-weekly intravenous bisphosphonate therapy in women with low risk bone metastases from breast cancer using bone resorption markers, .
14. Suppression of bone turnover following treatment with zoledronic acid in patients with metastatic breast cancer: duration of effect (SuBDuE), .
15. Duration of suppression of bone turnover following treatment with zole- dronic acid in men with metastatic castration resistant prostate cancer, .
16. A phase II, multi-centre, randomized, double-blind trial to evaluate the therapeutic benefit of fulvestrant in combination with ZACTIMA or Fulves- trant Plus placebo in postmenopausal women with bone only or bone predominant, hormone receptor positive metastatic breast cancer, < http:// clinicaltrials.gov/ ct2/show/NCT00811369>.
17. A multicentre study assessing 12-weekly intravenous bisphosphonate therapy in women with low risk bone metastases from breast cancer using bone resorption markers, phase II, .
18. A randomized, double-blind, placebo controlled, Phase III trial evaluating the palliative benefit of either continuing pamidronate or switching to second- line zoledronic acid in breast cancer patients with high risk bone metastases, < http://www.canadiancancertrials.ca/> .
19. A randomized double-blind, placebo-controlled phase iii study of early versus standard zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone, < http://clinicaltrials.gov/ct2/show/ NCT00079001>.
20. An open-label, multi-centre, phase 2 study of Denosumab in subjects with giant cell tumor of bone, < http://clinicaltrials.gov/ct2/show/ NCT00680992>.
21. A double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in subjects with non-metastatic prostate cancer receiving Denosumab for bone loss due to androgen-deprivation therapy, < http:// clinicaltrials.gov/ct2/show/NCT00925600>.
22. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma, < http://clinicaltrials.gov/ct2/show/NCT00742924>.
23. A randomized, double-blind, placebo-controlled, multi-centre phase 3 study of Denosumab as adjuvant treatment for women with early-stage breast cancer at high risk of recurrence, < http://clinicaltrials.gov/ct2/show/ NCT01077154>.
24. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer, < http://clinicaltrials.gov/ct2/show/NCT00127205>.
25. A randomized, single-blind, placebo-controlled, multicentre study to evaluate the effect of Risedronate and placebo on bone mineral density in men undergoing androgen deprivationtherapy with leuprolide acetate, < http:// clinicaltrials.gov/ct2/show/NCT00426777>.
26. A prospective study to evaluate the incidence of skeletal related events in prostate cancer patients undergoing Androgen Deprivation Therapy (ADT), < http://clinicaltrials.gov/ct2/show/NCT00632905> .
27. Prospective identification of risk factors for skeletal related events in breast cancer patients receiving bisphosphonates for bone metastases, < http:// clinicaltrials.gov/ct2/show/NCT01144481 >.
28. Histomorphometric and microarhitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer (MBC) patients on long term bisphosphonate therapy - a feasibility study, .
29. Bone repository feasibility study in breast, prostate and lung patients, < http://clinicaltrials.gov/ct2/show/> .
30. Breast cancer to bone (B2B) metastases research program: a multidisciplin- ary approach to the investigation of bone metastases from breast cancer, ww w.albertab2b.com.
31. A phase 2 trial exploring the clinical and correlative effects of combining Doxycycline with bone-targeted therapy in patients with metastatic breast cancer, < http://clinicaltrials.gov/ct2/show/>.
32. Cowan RW, Seidlitz EP, Singh G. Glutamate signalling in healthy and diseased bone. Frontiers in Endocrinology (Lausanne) 2012;3:89.
33. Seidlitz EP, Sharma MK, Singh G. Glutamate release in bone metastasis. Bone 2011;48(1):S32.
34. Hojjat SP, Beek M, Akens MK, Whyne CM. Can micro-imaging based analysis methods quantify structural integrity of rat vertebrae with and without metastatic involvement? Journal of Biomechanics 2012 Aug 1. [Epub ahead of print].
35. Lo VC, Akens MK, Moore S, Yee AJ, Wilson BC, Whyne CM. Beyondradiation therapy: photodynamic therapy maintains structural integrity of irradiated healthy and metastatically involved vertebrae in a pre-clinical in vivo model. Breast Cancer Research and Treatment 2012;135(2):391-401 [Epub 2012 Jul 12].
36. Quellet V, Tiedermann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E, et al. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. American Journal of Pathology 2011;178(5):2377-88.
37. Fathers KE, Bell ES, Rajadurai CV, Cory S, Zhao H, Mourskaia A, et al. Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Research 2012;14(3):R74 May 8 [Epub ahead of print].
38. Li J, Karaplis AC, Huang DC, Siegel PM, Camirand A, Yang XF, et al. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy targets. Journal of Clinical Investigation 2011;121(12):4655-69.
39. Howe GA, Addison CL. (51 integrin: an emerging player in the modulation of tumorigenesis and response to therapy. Cell Adhesion and Migration 2012;6(2):71-7 [Epub 2012 March 1].
40. Bouganim N, Amir E, Clemons M. BONUS 5: 5th Annual Bone and The Oncologist New Updates. Current Oncology 2010;17(4):113-8.
41. Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Research and Treatment 2011;129(3):761-5.
42. Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, et al. Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clinical & Experimental Metastasis 2009;26(8):935-43.
43. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treatment Reviews 2010;36:615-20.